GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innovent Biologics Inc (HKSE:01801) » Definitions » Net Margin %

Innovent Biologics (HKSE:01801) Net Margin % : -25.36% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Innovent Biologics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Innovent Biologics's Net Income for the six months ended in Dec. 2023 was HK$-972 Mil. Innovent Biologics's Revenue for the six months ended in Dec. 2023 was HK$3,833 Mil. Therefore, Innovent Biologics's net margin for the quarter that ended in Dec. 2023 was -25.36%.

The historical rank and industry rank for Innovent Biologics's Net Margin % or its related term are showing as below:

HKSE:01801' s Net Margin % Range Over the Past 10 Years
Min: -60901.16   Med: -63.91   Max: -16.56
Current: -16.56


HKSE:01801's Net Margin % is ranked better than
69.09% of 1032 companies
in the Biotechnology industry
Industry Median: -155.475 vs HKSE:01801: -16.56

Innovent Biologics Net Margin % Historical Data

The historical data trend for Innovent Biologics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovent Biologics Net Margin % Chart

Innovent Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Margin %
Get a 7-Day Free Trial -164.19 -25.97 -63.91 -47.83 -16.56

Innovent Biologics Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.11 -42.44 -53.04 -5.15 -25.36

Competitive Comparison of Innovent Biologics's Net Margin %

For the Biotechnology subindustry, Innovent Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innovent Biologics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innovent Biologics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Innovent Biologics's Net Margin % falls into.



Innovent Biologics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Innovent Biologics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin=Net Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-1124.31/6788.068
=-16.56 %

Innovent Biologics's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin=Net Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-972.111/3833.19
=-25.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovent Biologics  (HKSE:01801) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Innovent Biologics Net Margin % Related Terms

Thank you for viewing the detailed overview of Innovent Biologics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovent Biologics (HKSE:01801) Business Description

Traded in Other Exchanges
Address
168 Dongping Street, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Innovent Biologics, or Innovent, is one of the leading biotechnology companies in China. Listed on the Hong Kong Exchange in 2018, Innovent has eight commercialized oncology products and two commercialized non-oncology products as of August 2023. Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for the first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. It also has a wide spectrum of therapeutic targets in early clinical developments. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.

Innovent Biologics (HKSE:01801) Headlines

No Headlines